Loading…
← CockpitCompetitor Analysis › 4536.T Santen Pharmaceutical Co., Ltd.Open in the cockpit ↗

Santen Pharmaceutical Co., Ltd.4536.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharmaceutical company specializing in eye-care drugs and treatments, sold globally.

≈ A global ophthalmology-focused pharma, like a smaller Bausch + Lomb pharma armMomentum leader 88
Mkt cap
$4.14B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$17.0M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
+7.8 pp
WACC 5.0%
Hurdle
-8 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · JPY¥2,056
1D-0.3%
1W+3.1%
1M+19.1%
3M+7.2%
6M+10.5%
YTD+26.4%
1Y+35.0%
ATR %2.8%
52w lowhigh8.8% off high

What Santen Pharmaceutical does

Japanese pharmaceutical company specializing in eye-care drugs and treatments, sold globally.

Japan is the home market, where national insurance sets drug prices and cuts them in regular revisions, so growth leans on Asia, notably China, and Europe, and on new eye drugs. Sales are mostly prescription products reaching patients through eye doctors and hospitals.

In one line: A global ophthalmology-focused pharma, like a smaller Bausch + Lomb pharma arm.

Products and services

  • Prescription eye-drops/ophthalmic drugs
  • Ophthalmic surgical products

Customers

  • Ophthalmologists/hospitals
  • Patients with eye conditions

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Ophthalmology drug R&D, manufacturing…

What could go right

  • Aging population eye-disease prevalence

What could go wrong

  • Patent cliffs on key products
  • Generic competition

Moat: narrow (IP / patents, brand). Focused therapeutic-area expertise and patents in ophthalmology, a niche most large pharma underserve.

Headquarters: Osaka, Japan · Founded: 1890 · Employees: 3,968

Named competitors

Santen Pharmaceutical at a glance

Size Santen Pharmaceutical (4536.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $4.14B, the 290th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,056 on 18 Nov 2026.

Performance Over six months the shares gained 10.5%, against +0.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +5.8%); the operating margin is 15.8% (peer median 19.2%).

Valuation It trades at 16.7× forward earnings against a peer median of 25.2× (5th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 20264536.T 111Peer median 103
Six months, rebased to 100: Santen Pharmaceutical against the median of its 20 peers (local-currency closes).

Santen Pharmaceutical financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥297B¥292B¥300B¥302B¥279B
Revenue growth—-3%-1%+8%—
Gross profit¥167B¥155B¥163B¥164B¥157B
EBITDA¥64.9B¥63.6B¥74.2B¥70.1B¥49.3B
Net income¥38.9B¥37.4B¥36.2B¥26.6B-¥15.0B
Free cash flow¥41.3B¥36.7B¥54.3B¥63.3B¥19.9B
Capital expenditure¥13.6B¥14.3B¥11.0B¥10.7B¥24.6B
Total debt¥32.2B¥34.8B¥34.2B¥35.2B¥36.2B

Quarterly statements and history in the cockpit →

Santen Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%000100DFTX002294128940CAMX600566AJANTPHARM688336IONSTARSXENESLSEMCURE4536.T6-month return →1-month return →
Up and to the right = strong over both horizons. Santen Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×000100002294128940CAMX600566AJANTPHARM600332688336000513600329ROVIOGNEMCURE6005214536.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Santen Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%002294128940CAMX600566AJANTPHARM301569688336000513TARS4536.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Santen Pharmaceutical is the large dot.

Santen Pharmaceutical competitors and peer comparison

Head to head with its named competitors (4536.T vs ALC.SW vs BLCO.TO vs 4578.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Santen Pharmaceutical 4536.T$4.14B+10%+2%16%16.7×-5.0%
Alcon ALC.SW$36.9B+18%+1%12%21.5×12.2%
Bausch + Lomb BLCO.TO$7.41B+35%+11%9%18.3×12.0%
Otsuka Hldgs 4578.T$39.9B+9%+11%18%16.8×1.6%
Rohto Pharmaceutical 4527.T$3.87B+8%+7%12%16.5×-2.8%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%

How Santen Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Santen Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure4536.TPeer medianRank in peer set
1-month return+19.1%+0.2%3rd highest of 21
6-month return+10.5%+0.8%8th highest of 20
Distance from 52-week high-8.8%-26.4%5th highest of 21
Revenue growth (TTM)+1.9%+5.8%8th lowest of 19
Operating margin15.8%19.2%9th lowest of 18
Forward P/E16.7×25.2×5th cheapest of 15
Growth the price implies (Req g, 7 yrs)-5.0%6.4%3rd least demanding of 16
Growth delivered (Del g)+3.2%+7.5%6th lowest of 16
Hurdle (Req g minus delivered)-8.2 pp-3.1 pp7th least demanding of 16
ROIC minus cost of capital+7.8 pp+6.9 pp8th highest of 18
EV / EBITDA9.4×22.8×2nd cheapest of 9
Net debt / EBITDA-0.8×-0.1×3rd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%12.9×-0.7%+4.7%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%

Questions

Who are Santen Pharmaceutical's main competitors?
Named competitors: Alcon (ALC.SW), Bausch + Lomb (BLCO.TO), Otsuka Holdings (4578.T), Rohto Pharmaceutical (4527.T), Novartis (NOVN.SW), AbbVie (ABBV). The cockpit's measured peer set (industry) also includes Yuhan (000100.KS), Definium Therapeutics (DFTX), Shenzhen Salubris Pharmaceuticals (002294.SZ), HanmiPharm (128940.KS), Camurus (CAMX.ST), HUBEI JUMPCAN PHARMACEUTICAL (600566.SS).
Is Santen Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 25.2×, 5th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Santen Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +10.5% against +0.8% for the median peer; over one year +35.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.